Aarkstore - Telomerase Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Telomerase Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0f02-ZGRhO



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Telomerase Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Telomerase Activators-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Telomerase Activators. – PowerPoint PPT presentation

Number of Views:13

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Telomerase Inhibitors -Pipeline Insights, 2014


1
Telomerase Inhibitors -Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/76033/telomerase-inhibitors-pipeline-insights-20
    14

2
Summary
  • DelveInsights,Telomerase Inhibitors-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    mechanism of action (MOA). A key objective of the
    report is to establish the understanding for all
    the pipeline drugs that fall under Telomerase
    Inhibitors. This report provides information on
    the therapeutic development based on the
    Telomerase Inhibitors dealing with mechanism of
    action, comparative analysis at various stages
    covering Filed, Phase III, Phase II, Phase I, IND
    filed, Preclinical, Discovery and unknown stages,
    therapeutics assessment by monotherapy and
    combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Telomerase
    InhibitorsThe report provides pipeline products
    under drug profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the Telomerase Inhibitors
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    typeThe report reviews key players involved in
    the therapeutics development for Telomerase
    Inhibitors and also provide company profilingThe
    report also gives the information of dormant and
    discontinued pipeline projects Pipeline products
    coverage based on various stages of development
    ranging from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete MOA intelligence and
    complete understanding over therapeutics
    development for Telomerase InhibitorsIdentify
    the relationship between the drugs and use it for
    target finding, drug repurposing, and precision
    medicine.Devise corrective measures for pipeline
    projects by understanding Telomerase Inhibitors
    pipeline depth and focus of Indication
    therapeutics Developing strategic initiatives to
    support your drug development activities.Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and ScopeProvides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipelineGaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

7
Table of Content
  • Telomerase Inhibitors OverviewTelomerase
    Inhibitors Disease AssociatedTelomerase
    Inhibitors Pipeline TherapeuticsTelomerase
    Inhibitors Therapeutics under Development by
    Companies Telomerase Inhibitors Late Stage
    Products (Filed and Phase III)Comparative
    Analysis Telomerase Inhibitors Mid Clinical
    Stage Products (Phase II)Comparative
    Analysis Telomerase Inhibitors Early Clinical
    Stage Products (Phase I and IND
    Filed)Comparative Analysis Telomerase
    Inhibitors Discovery and Pre-Clinical Stage
    Products Comparative Analysis Drug Candidate
    ProfilesTelomerase Inhibitors Therapeutics
    Assessment Assessment by Monotherapy Products 

8
Table of Content
  • Assessment by Combination Products Assessment by
    Route of Administration Assessment by Molecule
    Type Telomerase Inhibitors Discontinued
    Products Telomerase Inhibitors Dormant
    ProductsCompanies Involved in Therapeutics
    Development for Telomerase Inhibitors Appendix M
    ethodology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for
    Telomerase Inhibitors by Therapy Area,
    2014Number of Products under Development for
    Telomerase Inhibitors, 2014Number of Products
    under Development by Companies Comparative
    Analysis by Late Clinical Stage Products (Filed
    and Phase III), 2014Comparative Analysis Mid
    Clinical Stage Products (Phase II),
    2014Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014Drug Candidates
    ProfilesTelomerase Inhibitors Assessment by
    Monotherapy Products Telomerase Inhibitors
    Assessment by Combination Products 

10
List of Tables
  • Telomerase Inhibitors Assessment by Route of
    Administration Telomerase Inhibitors Assessment
    by Stage and Route of Administration Telomerase
    Inhibitors Assessment by Molecule
    Type Telomerase Inhibitors Assessment by Stage
    and Molecule Type Telomerase Inhibitors
    Therapeutics Discontinued Products Telomerase
    Inhibitors Therapeutics Dormant ProductsProducts
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for
    Telomerase Inhibitors by Therapy Area,
    2014Number of Products under Development for
    Telomerase Inhibitors, 2014Late Clinical Stage
    Products (Filed and Phase III), 2014Mid Clinical
    Stage Products (Phase II), 2014Early Clinical
    Stage Products (Phase I and IND Filed),
    2014Discovery and Pre-Clinical Stage Products,
    2014Telomerase Inhibitors Assessment by
    Monotherapy Products Telomerase Inhibitors
    Assessment by Combination Products Telomerase
    Inhibitors Assessment by Route of
    Administration Telomerase Inhibitors Assessment
    by Stage and Route of Administration Telomerase
    Inhibitors Assessment by Molecule
    Type Telomerase Inhibitors Assessment by Stage
    and Molecule Type

12
Related Reports
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Recordati S.p.A. (REC) - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Global Gene Expression Market 2015-2019
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Telomerase Inhibitors -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Telomerase Inhibitors-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    mechanism of action (MOA).
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com